Are transglutaminase 2 inhibitors able to reduce gliadin-induced toxicity related to celiac disease? a proof-of-concept study

Journal of Clinical Immunology

Volumn 33, Issue 1, 2013, Pages 134-142

  Rauhavirta, Tiina ^a   Oittinen, Mikko ^a   Kivistö, Rami ^b   Männistö, Pekka T ^b   Garcia Horsman, J Arturo ^b   Wang, Zhuo ^c   Griffin, Martin ^c   Mäki, Markku ^a   Kaukinen, Katri ^d   Lindfors, Katri ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c ASTON UNIVERSITY   (United Kingdom)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Celiac disease; Gliadin; Small intestine; Transglutaminase 2 inhibitor

Indexed keywords

ACYLTRANSFERASE INHIBITOR; GLIADIN; INTERLEUKIN 15; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; R 281; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; GLUTEN; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ACTIN FILAMENT; ANTIBODY PRODUCTION; ARTICLE; CELIAC DISEASE; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CELL STRAIN CACO 2; CONTROLLED STUDY; CRYPT CELL; CULTURE MEDIUM; CYTOSKELETON; ELECTRIC RESISTANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE BIOPSY; INTESTINE CELL; INTESTINE EPITHELIUM; ORGAN CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; ORGAN CULTURE TECHNIQUE; PATHOLOGY; PHYSIOLOGY; PILOT STUDY; UPREGULATION;

CACO-2 CELLS; CELIAC DISEASE; DOWN-REGULATION; GLIADIN; GLUTENS; GTP-BINDING PROTEINS; HUMANS; INTESTINAL MUCOSA; ORGAN CULTURE TECHNIQUES; PILOT PROJECTS; TRANSGLUTAMINASES; UP-REGULATION;

MLCS; MLOWN;

EID: 84876437692     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-012-9745-5     Document Type: Article

References (35)

1. Sulkanen S, Halttunen T, Laurila K, et al. Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease. Gastroenterology. 1998;115:1322-8.
2. Kaukinen K, Collin P, Laurila K, Kaartinen T, Partanen J, Maki M. Resurrection of gliadin antibodies in coeliac disease. Deamidated gliadin peptide antibody test provides additional diagnostic benefit. Scand J Gastroenterol. 2007;42:1428-33.
3. Hallert C, Granno C, Hulten S, Midhagen G, Strom M, Svensson H, Valdimarsson T. Living with coeliac disease: controlled study of the burden of illness. Scand J Gastroenterol. 2002;37:39-42.
4. Sollid LM, Khosla C. Novel therapies for coeliac disease. J Intern Med. 2011;269:604-13.
5. Gundemir S, Colak G, Tucholski J, Johnson GV. Transglutaminase 2: a molecular Swiss army knife. Biochim Biophys Acta. 2012;1823:406-19.
6. Jones RA, Nicholas B, Mian S, Davies PJ, Griffin M. Reduced expression of tissue transglutaminase in a human endothelial cell line leads to changes in cell spreading, cell adhesion and reduced polymerisation of fibronectin. J Cell Sci. 1997;110:2461-72.
7. Griffin M, Casadio R, Bergamini CM. Transglutaminases: nature's biological glues. Biochem J. 2002;368:377-96.
8. Molberg O, Mcadam SN, Korner R, et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gutderived T cells in celiac disease. Nat Med. 1998;4:713-7.
9. Frisullo G, Nociti V, Iorio R, et al. Increased CD4+CD25+Foxp3+ T cells in peripheral blood of celiac disease patients: correlation with dietary treatment. Hum Immunol. 2009;70:430-5.
10. Gianfrani C, Levings MK, Sartirana C, et al. Gliadin-specific type 1 regulatory T cells from the intestinal mucosa of treated celiac patients inhibit pathogenic T cells. J Immunol. 2006;177:4178-86.
11. Maiuri L, Ciacci C, Ricciardelli I, et al. Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet. 2003;362:30-7.
12. Sander GR, Cummins AG, Henshall T, Powell BC. Rapid disruption of intestinal barrier function by gliadin involves altered expression of apical junctional proteins. FEBS Lett. 2005;579:4851-5.
13. Giovannini C, Maiuri L, De Vincenzi M. Cytotoxic effect of prolamin-derived peptides on in vitro cultures of cell line Caco-2: Implications for coeliac disease. Toxicol In Vitro. 1995;9:251-5.
14. Browning TH, Trier JS. Organ culture of mucosal biopsies of human small intestine. J Clin Invest. 1969;48:1423-32.
15. Stenman SM, Lindfors K, Korponay-Szabo IR, et al. Secretion of celiac disease autoantibodies after in vitro gliadin challenge is dependent on small-bowel mucosal transglutaminase 2-specific IgA deposits. BMC Immunol. 2008;9:6.
16. Lindfors K, Blomqvist T, Juuti-Uusitalo K, Stenman S, Venalainen J, Maki M, Kaukinen K. Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture. Clin Exp Immunol. 2008;152:552-8.
17. Juuti-Uusitalo K, Lindfors K, Maki M, Patrikainen M, Isola J, Kaukinen K. Inhibition of epithelial growth factor receptor signalling does not preserve epithelial barrier function after in vitro gliadin insult. Scand J Gastroenterol. 2009;44:820-5.
18. Griffin M, Mongeot A, Collighan R, Saint RE, Jones RA, Coutts IG, Rathbone DL. Synthesis of potent water-soluble tissue transglutaminase inhibitors. Bioorg Med Chem Lett. 2008;18:5559-62.
19. Baumgartner W, Golenhofen N, Weth A, Hiiragi T, Saint R, Griffin M, Drenckhahn D. Role of transglutaminase 1 in stabilisation of intercellular junctions of the vascular endothelium. Histochem Cell Biol. 2004;122:17-25.
20. Rauhavirta T, Qiao SW, Jiang Z, et al. Epithelial transport and deamidation of gliadin peptides: a role for coeliac disease patient immunoglobulin A. Clin Exp Immunol. 2011;164:127-36.
21. Maiuri L, Ciacci C, Ricciardelli I, et al. Unexpected role of surface transglutaminase type II in celiac disease. Gastroenterology. 2005;129:1400-13.
22. Jones RA, Kotsakis P, Johnson TS, Chau DY, Ali S, Melino G, Griffin M. Matrix changes induced by transglutaminase 2 lead to inhibition of angiogenesis and tumor growth. Cell Death Differ. 2006;13:1442-53.
23. Stenman SM, Venalainen JI, Lindfors K, et al. Enzymatic detoxification of gluten by germinating wheat proteases: implications for new treatment of celiac disease. Ann Med. 2009;41:390-400.
24. Thomas S, Brightman F, Gill H, Lee S, Pufong B. Simulation modelling of human intestinal absorption using Caco-2 permeability and kinetic solubility data for early drug discovery. J Pharm Sci. 2008;97:4557-74.
25. Molberg O, McAdam S, Lundin KE, Kristiansen C, Arentz-Hansen H, Kett K, Sollid LM. T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase. Eur J Immunol. 2001;31:1317-23.
26. Zanzi D, Stefanile R, Santagata S, et al. IL-15 interferes with suppressive activity of intestinal regulatory T cells expanded in Celiac disease. Am J Gastroenterol. 2011;106:1308-17.
27. Tiittanen M, Westerholm-Ormio M, Verkasalo M, Savilahti E, Vaarala O. Infiltration of forkhead box P3-expressing cells in small intestinal mucosa in coeliac disease but not in type 1 diabetes. Clin Exp Immunol. 2008;152:498-507.
28. Vorobjova T, Uibo O, Ojakivi I, Teesalu K, Panarina M, Heilman K, Uibo R. Lower expression of tight junction protein 1 gene and increased FOXP3 expression in the small bowel mucosa in coeliac disease and associated type 1 diabetes mellitus. Int Arch Allergy Immunol. 2011;156:451-61.
29. Maiuri L, Ciacci C, Auricchio S, Brown V, Quaratino S, Londei M. Interleukin 15 mediates epithelial changes in celiac disease. Gastroenterology. 2000;119:996-1006.
30. Barone MV, Zanzi D, Maglio M, et al. Gliadin-mediated proliferation and innate immune activation in celiac disease are due to alterations in vesicular trafficking. PLoS One. 2011;6:e17039.
31. Ciccocioppo R, Finamore A, Ara C, Di Sabatino A, Mengheri E, Corazza GR. Altered expression, localization, and phosphorylation of epithelial junctional proteins in celiac disease. Am J Clin Pathol. 2006;125:502-11.
32. Barone MV, Gimigliano A, Castoria G, et al. Growth factor-like activity of gliadin, an alimentary protein: implications for coeliac disease. Gut. 2007;56:480-8.
33. Koval M, Ward C, Findley MK, Roser-Page S, Helms MN, Roman J. Extracellular matrix influences alveolar epithelial claudin expression and barrier function. Am J Respir Cell Mol Biol. 2010;42:172-80.
34. Dieterich W, Esslinger B, Trapp D, et al. Cross linking to tissue transglutaminase and collagen favours gliadin toxicity in coeliac disease. Gut. 2006;55:478-84.
35. Lammers KM, Lu R, Brownley J et al. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology. 2008;135:194-204.e3.